Cargando…
Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients
The expression of classical human leukocyte antigen class I antigens (HLA‐I) on the surfaces of cancer cells allows cytotoxic T cells to recognize and eliminate these cells. Reduction or loss of HLA‐I is a mechanism of escape from antitumor immunity. The present study aimed to investigate the clinic...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419048/ https://www.ncbi.nlm.nih.gov/pubmed/32495519 http://dx.doi.org/10.1111/cas.14514 |
_version_ | 1783569806574747648 |
---|---|
author | Hiraoka, Nobuyoshi Ino, Yoshinori Hori, Shutaro Yamazaki‐Itoh, Rie Naito, Chie Shimasaki, Mari Esaki, Minoru Nara, Satoshi Kishi, Yoji Shimada, Kazuaki Nakamura, Naoya Torigoe, Toshihiko Heike, Yuji |
author_facet | Hiraoka, Nobuyoshi Ino, Yoshinori Hori, Shutaro Yamazaki‐Itoh, Rie Naito, Chie Shimasaki, Mari Esaki, Minoru Nara, Satoshi Kishi, Yoji Shimada, Kazuaki Nakamura, Naoya Torigoe, Toshihiko Heike, Yuji |
author_sort | Hiraoka, Nobuyoshi |
collection | PubMed |
description | The expression of classical human leukocyte antigen class I antigens (HLA‐I) on the surfaces of cancer cells allows cytotoxic T cells to recognize and eliminate these cells. Reduction or loss of HLA‐I is a mechanism of escape from antitumor immunity. The present study aimed to investigate the clinicopathological impacts of HLA‐I and non–classical HLA‐I antigens expressed on pancreatic ductal adenocarcinoma (PDAC) cells. We performed immunohistochemistry to detect expression of HLA‐I antigens in PDAC using 243 PDAC cases and examined their clinicopathological influences. We also investigated the expression of immune‐related genes to characterize PDAC tumor microenvironments. Lower expression of HLA‐I, found in 33% of PDAC cases, was significantly associated with longer overall survival. Higher expression of both HLA‐E and HLA‐G was significantly associated with shorter survival. Multivariate analyses revealed that higher expression of these three HLA‐I antigens was significantly correlated with shorter survival. Higher HLA‐I expression on PDAC cells was significantly correlated with higher expression of IFNG, which also correlated with PD1, PD‐L1 and PD‐L2 expression. In vitro assay revealed that interferon gamma (IFNγ) stimulation increased surface expression of HLA‐I in three PDAC cell lines. It also upregulated surface expression of HLA‐E, HLA‐G and immune checkpoint molecules, including PD‐L1 and PD‐L2. These results suggest that the higher expression of HLA‐I, HLA‐E and HLA‐G on PDAC cells is an unfavorable prognosticator. It is possible that IFNγ promotes a tolerant microenvironment by inducing immune checkpoint molecules in PDAC tissues with higher HLA‐I expression on PDAC cells. |
format | Online Article Text |
id | pubmed-7419048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74190482020-08-12 Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients Hiraoka, Nobuyoshi Ino, Yoshinori Hori, Shutaro Yamazaki‐Itoh, Rie Naito, Chie Shimasaki, Mari Esaki, Minoru Nara, Satoshi Kishi, Yoji Shimada, Kazuaki Nakamura, Naoya Torigoe, Toshihiko Heike, Yuji Cancer Sci Original Articles The expression of classical human leukocyte antigen class I antigens (HLA‐I) on the surfaces of cancer cells allows cytotoxic T cells to recognize and eliminate these cells. Reduction or loss of HLA‐I is a mechanism of escape from antitumor immunity. The present study aimed to investigate the clinicopathological impacts of HLA‐I and non–classical HLA‐I antigens expressed on pancreatic ductal adenocarcinoma (PDAC) cells. We performed immunohistochemistry to detect expression of HLA‐I antigens in PDAC using 243 PDAC cases and examined their clinicopathological influences. We also investigated the expression of immune‐related genes to characterize PDAC tumor microenvironments. Lower expression of HLA‐I, found in 33% of PDAC cases, was significantly associated with longer overall survival. Higher expression of both HLA‐E and HLA‐G was significantly associated with shorter survival. Multivariate analyses revealed that higher expression of these three HLA‐I antigens was significantly correlated with shorter survival. Higher HLA‐I expression on PDAC cells was significantly correlated with higher expression of IFNG, which also correlated with PD1, PD‐L1 and PD‐L2 expression. In vitro assay revealed that interferon gamma (IFNγ) stimulation increased surface expression of HLA‐I in three PDAC cell lines. It also upregulated surface expression of HLA‐E, HLA‐G and immune checkpoint molecules, including PD‐L1 and PD‐L2. These results suggest that the higher expression of HLA‐I, HLA‐E and HLA‐G on PDAC cells is an unfavorable prognosticator. It is possible that IFNγ promotes a tolerant microenvironment by inducing immune checkpoint molecules in PDAC tissues with higher HLA‐I expression on PDAC cells. John Wiley and Sons Inc. 2020-07-09 2020-08 /pmc/articles/PMC7419048/ /pubmed/32495519 http://dx.doi.org/10.1111/cas.14514 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Hiraoka, Nobuyoshi Ino, Yoshinori Hori, Shutaro Yamazaki‐Itoh, Rie Naito, Chie Shimasaki, Mari Esaki, Minoru Nara, Satoshi Kishi, Yoji Shimada, Kazuaki Nakamura, Naoya Torigoe, Toshihiko Heike, Yuji Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients |
title | Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients |
title_full | Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients |
title_fullStr | Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients |
title_full_unstemmed | Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients |
title_short | Expression of classical human leukocyte antigen class I antigens, HLA‐E and HLA‐G, is adversely prognostic in pancreatic cancer patients |
title_sort | expression of classical human leukocyte antigen class i antigens, hla‐e and hla‐g, is adversely prognostic in pancreatic cancer patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419048/ https://www.ncbi.nlm.nih.gov/pubmed/32495519 http://dx.doi.org/10.1111/cas.14514 |
work_keys_str_mv | AT hiraokanobuyoshi expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT inoyoshinori expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT horishutaro expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT yamazakiitohrie expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT naitochie expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT shimasakimari expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT esakiminoru expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT narasatoshi expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT kishiyoji expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT shimadakazuaki expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT nakamuranaoya expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT torigoetoshihiko expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients AT heikeyuji expressionofclassicalhumanleukocyteantigenclassiantigenshlaeandhlagisadverselyprognosticinpancreaticcancerpatients |